Treatment of progressive ovarian tumors with the therapeutic combination of the AcM Nimotuzumab and the NGGM3/VSSP vaccine
Authors
-
Raiza Ruiz
Hospital Ramón González Coro. La Habana, Cuba
https://orcid.org/0000-0001-6672-312X
- Daisy Hernández Hospital Ramón González Coro. La Habana, Cuba
-
Carmen Viada
Centro de Inmunología Molecular. La Habana, Cuba
https://orcid.org/0000-0002-1604-3545
-
Jessica García
Hospital Ramón González Coro. La Habana, Cuba
https://orcid.org/0000-0003-1397-048X
- Martha Fors Universidad de Las Américas, Quito, Ecuador
-
Mayra Ramos
Centro de Inmunología Molecular. La Habana, Cuba
https://orcid.org/0000-0002-9058-3224
DOI:
https://doi.org/10.70099/BJ/2024.01.04.13Keywords:
ovarian cancer, chemotherapy, immunotherapy, AcM Nimotuzumab, NGGM3/VSSP vaccineAbstract
Ovarian cancer ranks third among gynecological cancers and accounts for 4% of cancers in women. Antitumor immunotherapies constitute new therapeutic tools for identifying molecules differentially expressed in tumor cells. An exploratory study evaluated the safety and efficacy of a vaccine preparation containing NGlicolilGM3 (NGGM3/VSSP) and the Monoclonal Antibody Nimotuzumab (AcM CIMAher). Both products have proven to be safe and can be applied in combination with chemotherapy (QTP). Survival (OS) in patients who received QTP, AcM Nimotuzumab, and the NGGM3/VSSP vaccine was superior to those who did not receive chemotherapy. The antitumor effect of the combination may be synergistic since the therapies are directed at two tumor targets and act through different mechanisms.
References
1. Globocan 2021. The Global Cancer Observatory- May, 2021.
2. Siegel R L, Miller K D, Jemal A. Cancer Statistcs, 2018. Cancer J Clin 2018; 68:7-38.
3. Anuario Estadístico de Salud MINSAP 2018, Edición 2019. Anuario_Estadistico_de_salud_ISSN: versión electrónica 1561-4433. http://bvscuba.sld.cu//Anuario_Estadistico_Cuba//2018.
4. Liu G, Yang D, Sun Y, et al. Differing clinical impact of BCRA1 and BCRA 2 mutations in serous ovarian cancer. Pharmacogenomics 2012; 13: 1525-1535.
5. Varghese A, Lele S. Rare Ovarian Tumors. In: Lele S. editor. Ovarian Cancer. Brisbane (AU): Exon Publications. Online first 29 Jul 2022.
Doi: https://doi.org/10.36255/exon-publications-ovarian-cancer-rare-ovarian-tumor
6. Cancer Biol Med. 2020, 2. Ann Oncol. 2020
7. Prat J. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 2014; 124: 1-5. http//www.ncbi.nlm.nih.gov/pudmed/24219974.
8. Montero-Macías R , Rigolet P, Mikhael E, Krell J, Villefranque V, Lecuru F, and Fotopoulou C. Traditional Systemic Treatment Options in Advanced Low-Grade Serous Ovarian Cancer after Successful Cytoreduction: A Systematic Review and Meta-Analysis. Cancers 2022, 14, 3681. https://doi.org/10.3390/cancers14153681.
9. Bogani, G.; Maggiore, U.L.R.; Paolini, B.; Diito, A.; Martinelli, F.; Lorusso, D.; Raspagliesi, F. The detrimental effect of adopting interval debulking surgery in advanced stage low-grade serous ovarian cancer. J. Gynecol. Oncol. 2019, 30, e4. [CrossRef] [PubMed]
10. NCCN Clinical Practice Guidelines in Oncology. Ovarian Cancer including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 1. 2020. March 11, 2020.
11. Rebbeck T R, Mitran N, Wan F, et al. Association of type and location of BRCA1 and BRCA2 mutations whith risk breast and ovarian cancer. JAMA 2015; 313: 1347-1361.
12. Garcia Y G, Juan A D, Mendiola C, et al. Phase II randomized trial of neoadyuvan(NA) Chemotherapy (CT) whith or whithout Bevacizumab (Bev) in advancen ephithelial ovarian cancer (EOC) (GEICOROS/NOVA TRIAL). J Clin Oncol 2017; 35: Astrad 5508-5508.
13. du Bois A, Floquet A, Kim J W, et al. Incorporation of pazopanib in mantenance therapy of ovarian cancer. J Clin Oncol 2014; 32: 3374-3382.
14. Kaufman B, Shapira-Frommer R, Schmutzer R K, et al. Olaparib monotherapy in patients whith advanced and germline BRCA1/2 mutation. J Clin Oncol 2015; 33: 244-250.
15. Xu S, Ramos Suzarte M, Bai X, Xu B. Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience. www.impactjournals.com/oncotarget/ 2016
16. Wang XQ, Sun P, Paller AS. Ganglioside induces caveolin-1 redistribution and interaction with the epidermal growth factor receptor. J Biol Chem 2002;277(49):47028-34.
17. Roque-Navarro L, Chakrabandhu K, de Leon J, Rodriguez S, Toledo C, Carr A, de Acosta C M, Hueber A O and Perez R. Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity. Mol Cancer Ther, 7: 2033-2041, 2008
18. Informe final EC Fase I/II “Ensayo Clínico con la vacuna NGcGM3/VSSP aplicada por vía subcutánea en el tratamiento de pacientes con cáncer de mama avanzado”. Código IIC RD-EC 067.
19. Shih K K, Zhou Q C, Aghajanian C, Huh J, Soslow R A, Morgan J C, et al. Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors. Gynecol Oncol. 2010;119(2):270-3. https://doi.org/10.1016/j.ygyno.2010.07.019.
20. du Bois A, Ewald-Riegler N, de Gregorio N, Reuss A, Mahner S, Fotopoulou C, et al. Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynakologische Onkologie (AGO) Study Group. Eur J Cancer. 2013;49(8):1905-14. https://doi.org/10.1016/j.ejca.2013.01.035.
21. Cornelison, R.; Llaneza, D.C.; Landen, C.N. Emerging therapeutics to overcome chemoresistance in epithelial ovarian cancer: A mini-review. Int. J. Mol. Sci. 2017, 18, 2171. [CrossRef]
22. Lukanovic´, D.; Herzog, M.; Kobal, B.; Cˇ erne, K. The contribution of copper efflux transporters ATP7A and ATP7B to chemoresistanceand personalized medicine in ovarian cancer. Biomed. Pharm. 2020, 129, 110401. [CrossRef] [PubMed]
23. Colombo, N.; Sessa, C.; du Bois, A.; Ladermann, J.; McCluggage, W.G.; McNeish, I.; Morice, P.; Pignata, S.; Ray-Coquard, I.; Vergote, I.; et al. ESMO–ESGO Ovarian Cancer Consensus Conference Working Group, ESMO–ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann. Oncol. 2019, 30, 672–705. [CrossRef]
24. Zobec Logar, H.B.; Smrkolj, Š.; Merlo, S.; Bebar, S.; Kobal, B.; Škof, E.; Cerar, O.; Cvjeti´canin, B.; Vakselj, A.; Šešek, M.; et al. Smernice za Obravnavo Bolnic z Rakom Jajˇcnikov, Jajcevodov in s Primarnim Peritonealnim Seroznim Rakom, 2nd ed.; Združenje za Radioterapijo in Onkologijo SZD, Združenje za Ginekološko Onkologijo, Kolposkopijo in Cervikalno Patologijo SZD, Onkološki Inštitut: Ljubljana, Slovenia, 2016.
25. Lawrie, T.A.; Rabbie, R.; Thoma, C.; Morrison, J.; Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group. Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer. Cochrane Database Syst. Rev. 2013, 10, CD010482.
26. Pignata, S.; Scambia, G.; Katsaros, D.; Gallo, C.; Pujade-Lauraine, E.; De Placido, S.; Bologna, A.; Weber, B.; Raspagliesi, F.; Panici, P.B.; et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): A randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2014, 15, 396–405. [CrossRef]
27. Falandry, C.; Rousseau, F.; Mouret-Reynier, M.A.; Tinquaut, F.; Lorusso, D.; Herrstedt, J.; Savoye, A.M.; Stefani, L.; Bourbouloux, E.; Sverdlin, R.; et al. Efficacy and safety of first-line single-agent carboplatin vs carboplatin plus paclitaxel for vulnerable older adult women with ovarian cancer: A GINECO/GCIG randomized clinical trial. JAMA Oncol. 2021, 7, 853–861. [CrossRef] [PubMed]
27. Garrido G, Tikhomirov I A, Rabasa A, Yang E, Gracia E, Iznaga N, et al. Bivalent binding by intermediate affinity of nimotuzumab: A contribution to explain antibody clinical profile. Cancer Biol Ther 2011; 11:373–82. http://dx.doi.org/10.4161/cbt.11.4.14097.
28. Bebb G, Boland W and Melosky B. Dontt jump to rash conclusions. Cancer Biol Ther 2011; 11: 639–41. http://dx.doi.org/10.4161/cbt.11.7.14920.
29. Gershenson DM, Bodurka DC, Lu KH, Nathan LC, Milojevic L, Wong KK, et al. Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor. J Clin Oncol. 2015;33(24):2675-82. https://doi.org/10.1200/JCO.2015.61.0873
30. Lee, E.K.; Matulonis, U.A. PARP Inhibitor resistance mechanisms and implications for post- progression combination therapies. Cancers 2020, 12, 2054. [CrossRef].
Published
How to Cite
Issue
Section
Categories
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with BioNatura Journal agree to the following terms: Authors retain copyright and grant the BioNatura Institutional Publishing Consortium (BIPC) right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). This allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
